Stem Cell-Derived Exosomes

Business News

ELEVAI Labs Posts Q3 2023 Earnings, Reports Record Quarterly Revenue

ELEVAI Labs (NASDAQ: ELAB), a medical aesthetic company specializing in physician-dispensed skincare, today reported its fiscal 2023 Q3 financial results.…

Read More »
Business News

ELEVAI Labs Expands Into European Market With Signing of New Partnership

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare is pleased to announce its new partnership with…

Read More »
Wealthy Biotech Trader

ELEVAI Labs Inks Licensing Deal With Yuva Biosciences to Develop New Topical Skincare Formulations and Aesthetics Products (VIDEO)

ELEVAI Labs (NASDAQ: ELAB) a medical aesthetic company specializing in physician-dispensed skincare, announced today the signing of a licensing agreement…

Read More »
Business News

ELEVAI Labs to Accelerate and Expand its Work With Stem Cell-Derived Exosomes After Securing New Research Partnership and Non-Repayable Grant

ELEVAI Secured its Non-Repayable Grant From the Mitacs Accelerate Grants Program (Mitacs) and Will Be Conducting its Research Partnership With…

Read More »
Back to top button